TY - JOUR
T1 - Acute activation of metabolic syndrome components in pediatric acute lymphoblastic leukemia patients treated with dexamethasone
AU - Warris, Lidewij T.
AU - Van Den Akker, Erica L T
AU - Bierings, Marc B.
AU - Van Bos, Cor Den
AU - Zwaan, Christian M.
AU - Sassen, Sebastiaan D T
AU - Tissing, Wim J E
AU - Veening, Margreet A.
AU - Pieters, Rob
AU - Van Den Heuvel-Eibrink, Marry M.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Although dexamethasone is highly effective in the treatment of pediatric acute lymphoblastic leukemia (ALL), it can cause serious metabolic side effects. Because studies regarding the effects of dexamethasone are limited by their small scale, we prospectively studied the direct effects of treating pediatric ALL with dexamethasone administration with respect to activation of components of metabolic syndrome (MetS); in addition, we investigated whether these side effects were correlated with the level of dexamethasone. Fifty pediatric patients (3-16 years of age) with ALL were studied during a 5-day dexamethasone course during the maintenance phase of the Dutch Childhood Oncology Group ALL-10 and ALL-11 protocols. Fasting insulin, glucose, total cholesterol, HDL, LDL, and triglycerides levels were measured at baseline (before the start of dexamethasone; T1) and on the fifth day of treatment (T2). Dexamethasone trough levels were measured at T2. We found that dexamethasone treatment significantly increased the following fasting serum levels (P3.4) from 8% to 85% (P
AB - Although dexamethasone is highly effective in the treatment of pediatric acute lymphoblastic leukemia (ALL), it can cause serious metabolic side effects. Because studies regarding the effects of dexamethasone are limited by their small scale, we prospectively studied the direct effects of treating pediatric ALL with dexamethasone administration with respect to activation of components of metabolic syndrome (MetS); in addition, we investigated whether these side effects were correlated with the level of dexamethasone. Fifty pediatric patients (3-16 years of age) with ALL were studied during a 5-day dexamethasone course during the maintenance phase of the Dutch Childhood Oncology Group ALL-10 and ALL-11 protocols. Fasting insulin, glucose, total cholesterol, HDL, LDL, and triglycerides levels were measured at baseline (before the start of dexamethasone; T1) and on the fifth day of treatment (T2). Dexamethasone trough levels were measured at T2. We found that dexamethasone treatment significantly increased the following fasting serum levels (P3.4) from 8% to 85% (P
UR - http://www.scopus.com/inward/record.url?scp=84977497336&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0158225
DO - 10.1371/journal.pone.0158225
M3 - Article
C2 - 27362350
AN - SCOPUS:84977497336
SN - 1932-6203
VL - 11
JO - PLoS ONE [E]
JF - PLoS ONE [E]
IS - 6
M1 - e0158225
ER -